Biotech's Global Event. Customized for You - View Special Pull-Out Section - June 27-30, 2011 Monday-Thursday - Sardegna Ricerche
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Breakthroughs. View Special Pull-Out Section
Biotech’s
Global Event.
Customized
for You.
Partnerships.
Leadership.
June 27-30, 2011
Monday-Thursday
Walter E. Washington
Convention Center
Washington DC USA
convention.bio.org
Italian Trade Commission Los Angeles Italian Trade Commission Los Angeles
PASSION. POTENTIAL. PROVEN.
VISIT ThE ITALIAN PAVILION AT BIO 2011
hALL A / BOOTh 2237
Areta International, Artenergy Publishing, Bio Industry Park Silvano Fumero Spa-Biopmed Cluster, Bio-Ker,
Camera Di Commercio Di Torino, Ceipiemonte, Cisi, Consorzio Interdisciplinare Di Studi Biomolecolari Ed
Applicazioni Industrali, Crom, Molmed Spa, Naicons, Nanovector, Nerviano Medical Sciences Oncology,
Nuova Ompi, Pharma & Biotech Advisors, Progefarm, Promos, Promosiena, Proteogen Bio, Sardegna Ricerche,
Technorizon, Toscana Life Science Foundation, Toscana Promozione, Zebra Venture.
MEET ITALY AT
Contents
Solutions for Your Business…Found at BIO
View Special
Find partners, sustain BIO Business Forum Pull-Out Section
projects and funding powered by BIO One-on-One Partnering™ p.8
Emerging markets that are Super Session — Emerging Markets:
shaping business The Future of Growth for Biologics? p.11
TABLE OF CONTENTS
Strong patent protection Breakout Sessions — Biotech
and key trends in licensing Patenting and Tech Transfer Track p.16 4 People You’ll Meet at BIO
5 Companies You’ll See at BIO
Managing early-stage Breakout Sessions —
company dynamics Business Development Track p.16 6 Schedule of Events
8 Partnering at BIO
Contract research and BIO Exhibition — Contract Services
manufacturing Zone and Summit p.30 10 Keynote Luncheons
Venture philanthropy options — 11 Super Sessions
Patient and Health Advocacy
finding a successful model Community at BIO p.32
12 BIO Program Overview
13 Breakout Sessions
26 Special Programs and
Co-Located Events
Sponsors as of March 25, 2011
29 Evening and Networking
Double Helix Sponsors Events
30 BIO Exhibition
32 BIO Pavilion
32 Regional Overview
33 BIO Exhibitor List
(Continues on Back Cover)
35 myBIO Overview
36 Housing and Travel
38 Registration Packages
39 Sponsors
2011 BIO International
Convention Regional Hosts
Helix Sponsors
For more information and to register, visit convention.bio.org + 1.202.962.6655 3
People You’ll Meet at BIO
C-Level Leaders and Policy Makers
from Around the Globe
More than 80 international public officials and policy
makers. Influential U.S. governors and congressmen.
Executives and their teams being groomed for Meet a Full Range of Executives...
leadership. People with new perspectives and vital 2010 Attendance
by Job Level
connections. Meet them all at BIO.
33% Managers
28% Executive
Management
24% Directors
15% C-Level
1 out of 3 BIO Attendees Comes from Outside the U.S.
...From Companies of All Sizes
2010 Company
Size Breakdown
by # of Staff
40% Large
33% Medium
27% Small
Small: 1-19
Medium: 20-499
Large: 500+
The Americas Europe Asia/Pacific Middle East Africa
International Delegations: If you are coming to the U.S.
for BIO, visit convention.bio.org/international.
Attention: International Attendees “BIO is the global marketplace for
Be sure to stop by the International Lounge to get our industry. The depth of content,
away from the convention crowd, network with opportunities for stakeholders and
colleagues, make new connections and enjoy biotech companies to present
benefits such as — themselves are rich and meaningful.
• private meeting rooms Results achieved at BIO give our
• afternoon beverage service industry a quiver full of activities,
• computer and internet access especially when Washington, D.C.
• and more! is the meeting place.”
The International Lounge is open from Monday Domenico Alexakis
through Thursday. For daily hours and location, CEO, Swiss
visit convention.bio.org/schedule. Biotech Association
4 B I O I N T E R N AT I ON A L CON V E N T I ON • June 27–30, 2011, Monday–Thursday
Companies You’ll See at BIO
The Most Innovative, Powerful Companies in Biotech
Solutions Providers?
In the BIO Exhibition
Join the myBIO Company Network
With 1,700+ exhibitors organized into
Pavilions and Product Focus Zones, you’re The myBIO Company Network contains BIO
sure to find companies who can help move Exhibitors, Partnering Companies, Presenting
your project forward — no matter the field Companies, Sponsors and BIO members, all in
or stage in the process. one spot. Visit convention.bio.org/myBIO to
connect with the community, view company
See page 33 for a list of exhibitors or profiles and build your event plan.
browse the myBIO Company Network.
Powerful Sponsor Companies? Search by keyword Send messages to exhibitors
Everywhere at BIO to find companies you want to visit and add
Anchoring the BIO Program, BIO that interest you. them to your event plan.
Exhibition, BIO Business Forum and
myriad networking events, the biggest Review
players in biotech — and supporters of the companies
industry —
come to lend their experience, participating
in the BIO
energy and power to attendees like you. Business Forum
BIO sponsors are listed on page 39 and
in the myBIO Company Network.
Potential Partners and
New Industry Players?
In the BIO Business Forum
Thousands of companies from around the
world and all industry segments will be at
BIO, ready to build strategic partnerships
that bring innovations to market. Find them
using the BIO One-on-One PartneringTM
View profiles with company overviews, representatives
system and schedule face-to-face attending BIO and types of participation such as
meetings in the BIO Business Forum. Partnering, Presenting and Exhibiting.
And be sure to see up-and-coming
innovators — including Buzz of BIO
winners — give hundreds of 15-minute See pages 8 – 9 or visit convention.bio.org/businessforum for details on Company
Company Presentations about their newest Presentations, BIO Business Forum Partnering and how to maximize your ROI with
ideas and most compelling research. BIO One-on-One Partnering.
Find Solutions Every Step of the Way, Across All Industry Segments
Research & Drug Development
Royalty & Development
Development
Find what interests you at BIO
Business Drug Discovery
Inventions
Models
Drug Delivery Imaging Keyword: Drug Development
Biomanufacturing Micro Arrays Search results
Products
and Cell Biology Nanotechnology People
Services Assessments
Medical Devices Pharmacogenomics Manager, Business Development at Alkermes
Plant-Made Chairman and CEO at Otologic Pharmaceutics, Inc.
Genomics
Pharmaceuticals Companies
Stem Cell Research
Licensing Proteomics ALMAC, Booth 1511
Intellectual Bioinformatics
Property Development Center for Biotechnology, Booth 4513
Screening
Marketing
Protection Biofuels Sessions and Events
Transgenics A New Clinical Operations Model:
Aquaculture
Gene/Cell Therapy Proactive Planning at Work
Animal-Made Are Diagnostic Reimbursement Policies
Pharmaceuticals And more! Impeding Personalized Medicine?
For more information and to register, visit convention.bio.org + 1.202.962.6655 5
Schedule of Events
Saturday, June 25
Can’t-Miss Monday FOCUS ON NETWORKING
Registration/Information &
Monday’s special programs feature
Housing Open
some of the biggest names in We’re hosting hundreds of events
1:00 pm – 6:00 pm biotech. Add them to your event plan during the convention!
at convention.bio.org/myBIO. Visit convention.bio.org/schedule to—
Sunday, June 26 • See the various meetups
Registration/Information & FOCUS ON LEADERSHIP scheduled during BIO.
• Make plans for Tuesday’s
Housing Open Open Night by checking out the
7:00 am – 6:00 pm Biotech Primer: Bio-Baffled? BIO Party List.
10:00 am – 12:00 pm
Biotechnology Entrepreneurship • View all Exhibitor Hospitality Receptions
Boot Camp and Reception Leadership Summit: Deploying happening on Tuesday evening.
Agricultural and Industrial • Get updates on exhibitor raffles,
8:00 am – 7:30 pm
Biotechnologies to Meet affiliated events and more!
Development Challenges
Monday, June 27 1:00 pm – 4:15 pm
Registration/Information & Translational Research Forum and NEW
Housing Open Reception: Translational Medicine Emerging Leaders
7:00 am – 7:00 pm — A Global Endeavor
1:00 pm – 6:00 pm Emerging Leaders Workshop:
BIO Golf Outing
Hitting the Mark in New Product
8:00 am – 4:00 pm
Breakout Sessions Commercialization
BIO Executive Presentation Workshop 2:00 pm – 5:00 pm 8:45 am – 12:30 pm
8:00 am – 5:30 pm BIO Career Fair
Biotechnology Entrepreneurship 2:00 pm – 7:00 pm BIO Business Forum Company
Boot Camp Welcome Reception at the Newseum Presentations
8:15 am – 5:30 pm 7:15 pm – 9:00 pm 9:00 am – 11:00 am
BIO 5K Run/Walk
Tuesday, June 28
8:30 am – 10:30 am From intellectual property services to
Registration/Information & Housing Open data analysis and storage technologies
7:00 am – 6:30 pm — the BIO Exhibition is where you will
NEW BIO Business Forum Partnering
get the tools to meet the challenges of
Emerging Leaders Meeting Desk Open
this increasingly complex industry.
8:00 am – 6:00 pm
Emerging Leaders Workshop: Biotechnology Entrepreneurship Boot Camp FOCUS ON BREAKTHROUGHS
Hitting the Mark in New Product 8:30 am – 12:15 pm
Commercialization BIO Exhibition Ribbon Cutting
Breakout Sessions &
8:45 am – 5:00 pm Ceremony
International Case Studies
8:30 am – 5:00 pm 9:45 am – 10:00 am
BIO Exhibition Open
For complete descriptions, speakers and locations and to add any of these events to
your event plan, visit convention.bio.org/myBIO. 10:00 am – 6:30 pm
Super Session: Ernst & Young’s 25th
Start Your Event Plan Now with myBIO. Annual Biotechnology Industry Report
Visit convention.bio.org/myBIO to— 10:00 am – 11:30 am
• Search for sessions and events by keyword. BIO Business Forum Partnering
• Browse speaker profiles and their sessions as well as 10:00 am – 5:00 pm
attendees and exhibitor personnel schedules at BIO.
• Find profiles of companies that interest you and Keynote Luncheon
communicate with their team before the convention. 12:00 pm – 2:00 pm
• Build an event plan that meets your needs so you Contract Services Summit
don’t miss a thing!
2:15 pm – 5:00 pm
6 B I O I N T E R N AT I ON A L CON V E N T I ON • June 27–30, 2011, Monday–Thursday
Schedule of Events
Super Session: Burrill State-of-the- Keynote Luncheon
Industry Report
2:00 pm – 3:30 pm
12:00 pm – 2:00 pm
Co-Located Events
Super Session: Campbell Alliance 2011
These events require a separate
BIO Business Forum Company Dealmakers’ Intentions
registration or RSVP.
Presentations 2:00 pm – 3:30 pm Visit convention.bio.org for full
2:00 pm – 4:00 pm descriptions, pricing and locations.
BIO Business Forum Company
Super Session: It Takes a Village — Presentations
The Biotechnology Innovation Ecosystem BIO-LES Business
2:00 pm – 4:00 pm Development Basics
3:45 pm – 5:15 pm
BIO Exhibition Power Hours Saturday, June 25, 7:30 am – 7:30 pm
BIO Exhibitor Hospitality Receptions 3:45 pm – 5:00 pm Sunday, June 26, 7:30 am – 4:00 pm
5:00 pm – 6:30 pm Monday, June 27, 7:30 am – 4:00 pm
Super Session — Worldview 2011:
Scientific American’s Regional AURP Bio GreenTech Parks 2011
Tuesday: Open Night in Washington Bio-Innovation Scorecard Saturday, June 25 – Sunday, June 26,
View the BIO Party List at 3:45 pm – 5:15 pm
convention.bio.org/schedule. 8:00 am – 5:00 pm
Think & Drink Discussion Forum: 8th Annual Community College
Innovation Politics — From Capitol Hill Program
to the Campaign Trail
Wednesday, June 29 Sunday, June 26, 8:00 am – 5:00 pm
5:00 pm – 6:30 pm
BIO Business Forum Partnering International Reception Biotech Primer: Biotech for the
Meeting Desk Open Non-Scientist
5:15 pm – 6:15 pm
7:00 am – 5:30 pm Sunday, June 26, 8:30 am – 4:30 pm
Gala Reception at Union Station
Registration/Information & Housing Open BIO Human Resources
7:45 pm – 9:30 pm
8:00 am – 5:00 pm Conference 2011
Sunday, June 26, 4:00 pm – 8:00 pm
Thursday, June 30 Monday, June 27, 7:00 am – 7:00 pm
Don’t miss the opportunity to build a Tuesday, June 28, 7:00 am – 4:00 pm
strategic partnership that ensures BIO Business Forum Partnering
your long-term value in the biotech Meeting Desk Open Partnering for Global Health (PGH)
industry. Visit convention.bio.org/ 7:00 am – 5:30 pm Forum and Reception
businessforum to learn more. Monday, June 27, 8:30 am – 4:30 pm;
Registration/Information & Housing Open Reception, 5:30 pm – 7:00 pm
8:00 am – 2:30 pm
FOCUS ON PARTNERSHIPS BIO Business Forum Partnering
2011 Biosecurity Conference
Wednesday, June 29, 8:15 am – 5:15 pm
8:00 am – 5:00 pm Thursday, June 30, 8:15 am – 2:00 pm
BIO Business Forum Partnering
8:00 am – 5:00 pm Diabetes Forum — Emerging Strategies,
Challenges and Partnerships
8:30 am – 11:00 am Diversity Summit and
Breakout Sessions & Reception
International Case Studies Breakout Sessions & Monday, June 27, 12:00 pm – 3:30 pm
8:30 am – 3:30 pm International Case Studies
8:30 am – 11:30 am
Diabetes Forum and Reception —
Emerging Strategies, Challenges and BIO Business Forum Company
FOCUS ON DIVERSITY
Partnerships Presentations
8:30 am – 6:00 pm Interested in diversity-related
9:00 am – 11:00 am
programming at BIO?
BIO Business Forum Company BIO Exhibition Open Visit convention.bio.org/myBIO
Presentations 10:00 am – 2:00 pm and search keyword “diversity.”
9:00 am – 11:00 am
BIO Exhibition Power Hours
Super Session: Emerging Markets — 11:30 am – 2:00 pm See Special Wednesday Receptions
The Future of Growth for Biologics on page 29.
10:00 am – 11:30 am BIO Business Forum Company
Presentations
BIO Exhibition Open 1:00 pm – 3:00 pm
10:00 am – 5:00 pm
For more information and to register, visit convention.bio.org + 1.202.962.6655 7
Partnering at BIO
How Will You Meet Your Next Partner?
Efficiently. Economically. At BIO.
Collaboration Begins in the BIO Business Forum.
Come to BIO with a team, ready to discuss your strategic goals. Thousands of companies
from around the world and across all industry segments will be in the BIO Business
Forum with a shared goal — to build relationships that lead to successful partnerships
and breakthrough solutions. Visit convention.bio.org/businessforum for details.
“BIO Business Forum provides “Biotech, pharma, universities,
efficient and high access to the right investors...they’re all here.”
players for business development.”
International Distribution Industry Type
(2010 Business Forum Participants) (2010 Business Forum Participants)
58% North America 41% Biotech
29% Europe 18% Pharma
16% CRO/Service
10% Academic/Tech Transfer
9% Asia
10% Investor and Other
4% Other 5% Government/Econ. Dev.
Powerful Companies Partner at BIO
Sponsors: • Genentech “The BIO Business Forum is a very
• Abbott • GlaxoSmithKline efficient tool for partnering. Where
• Amgen • Human Genome Sciences Inc else can you find companies from
• AstraZeneca • Johnson & Johnson
around the globe in one location with
• Baxter International Inc • MedImmune
• Bayer HealthCare • Merck the desire to look for opportunities?
• Boehringer Ingelheim • Novo Nordisk Inc The savings in travel alone is worth
• Campbell Alliance • Novozymes the price of admission.”
• Daiichi Sankyo • Pfizer Russell Herndon
• Elan Drug Technologies • Roche President & CEO
• Eli Lilly and Company • sanofi-aventis Hydra Biosciences
• EMD Serono, Inc • sanofi pasteur
• FedEx • Takeda Pharmaceuticals, Inc
• Forest Laboratories, Inc • Teva Pharmaceutical Industries Ltd
• Upsher-Smith Laboratories, Inc
8 B I O I N T E R N AT I ON A L CON V E N T I ON • June 27–30, 2011, Monday–Thursday
Planning Your Participation
Interested in partnering at BIO? Here’s Plan Ahead with BIO One-on-One Partnering
what you should know ahead of time:
Maximize your partnering success—
use BIO One-on-One Partnering to:
Registration Information BIO One-on-One Partnering
• Search for industry executives
Choose Full Convention Access and The industry’s most efficient
and companies. partnering system
Partnering—your best value*
• Communicate with participants
Save up to 40% when Early Bird Rate and schedule partnering meetings.
you register by May 19. (before 5/19/11) After 5/19/11
Members $1,740 $2,440 • Pinpoint the best opportunities for 17,000+ 2,100+
your business — explore potential face-to-face participating All in 3 days
Non-members $2,490 $3,140 meetings companies
investors, licensing agreements
Includes access to BIO One-on-One Partnering, and ways to enhance product
Education, BIO Exhibition and Evening Events. pipeline development.
*Partnering included when you register Visit convention.bio.org/businessforum for details.
for Convention Access and Partnering.
See page 38 for details.
ADDED VALUE! All Full Convention
Access — or Convention Access —
and Partnering registrants receive
Hear the Next Big Idea
FREE access to the MedTRACK Hundreds of new industry players—including the Buzz of BIO winners—
will be delivering 15-minute Company Presentations in the BIO Business
database for the month of June.
Forum covering a variety of areas, including:
Visit convention.bio.org/businessforum
for details. • Leading Biotech/Big Pharma • Non-Profits/Patient Advocacy
• Exciting innovations from the Buzz of BIO winners
Improve Your Company Presentation Watch this year’s Buzz of BIO winners at
convention.bio.org/businessforum to get a preview of what’s in store.
To hone your pitching skills before your
Company Presentation, register early Company Presentation Hours:
for the popular Executive Presentation Tuesday, June 28, 9:00 am – 11:00 am and 2:00 pm – 4:00 pm
Workshop on Monday, June 27. Wednesday, June 29, 9:00 am – 11:00 am and 2:00 pm – 4:00 pm
Thursday, June 30, 9:00 am – 11:00 am and 1:00 pm – 3:00 pm
BIO Business Forum Hours
Tuesday, June 28........... 10:00 am – 5:00 pm ➥Add to your myBIO event plan at convention.bio.org/myBIO.
Wednesday, June 29.....8:00 am – 5:00 pm Are you the Buzz of BIO? Tell us your story and you could win a
Thursday, June 30......... 8:00 am – 5:00 pm free registration. Visit convention.bio.org/businessforum for details.
Business Forum Wine & Cheese Reception
Wednesday, June 29, 5:00 pm – 6:00 pm
QUESTIONS?
“For a small company with a
A 10-Step Plan for
Successful Partnering tight budget, the BIO Business
Forum provides the best
1. Complete your company profile.
2. Research potential partners and make
bang for the buck.”
your target list. Paul Radspinner
President & CEO
3. Consider options beyond big pharma. FluGen
4. Perform competitive intelligence.
George Rena’e
5. Send meeting requests early.
6. Customize your requests. Contact George, Rena’e or any member
7. Plan your follow-up on invitations. of our Customer Service Team.
8. Use social media, email and Phone: +1.866.356.5155;
press releases to publicize that you’ll be +1.202.962.6666
partnering at BIO.
Email: biopartnering@bio.org
9. Bring the right personnel.
Don’t attend alone. Read our blog:
10. Bring business cards, printouts blogs.bio.org/bio1x1partnering
of company profiles and a Visit: convention.bio.org/
concise list of your goals. businessforum.
For more information and to register, visit convention.bio.org + 1.202.962.6655 9
Keynote Luncheons
What Do You Need to Keep Pace with the Pulse of the Industry?
BIO Program sessions put you on the forefront of biotech’s most important developments.
Global Perspective
KEYNOTE LUNCHEONS
TUESDAY 12:00 pm – 2:00 pm
An Interview with Tony Blair
Former Prime Minister of Great Britain and
Northern Ireland, Tony Blair shares his unique
perspective on global issues.
Sponsored by:
“Mr. Blair’s vast experience as a global leader will provide our audience with
helpful and inspirational insights as we continue our industry’s global mission
to heal, fuel and feed the world.”
State of the Industry Address
James C. Greenwood
President and CEO
Biotechnology Industry Organization
WEDNESDAY 12:00 pm – 2:00 pm
Join us for a keynote panel about the future of healthcare reform
moderated by BIO’s President and CEO, Jim Greenwood.
Sponsored by:
Keynote Luncheons are open exclusively to Full or Convention Access registrants.
Visit convention.bio.org/schedule for full event and session descriptions.
“The BIO International Convention brings together the Awards
most influential leaders in biotech from around the Awards presented during the
world. As a small biotech company, we greatly value Tuesday Keynote Luncheon:
the opportunity to meet with multiple companies in The International BioGENEius
one place at one time. Last year, we met with Challenge Awards
more than 25 companies that represented Biotechnology Heritage Award
significant business opportunities for us.” Awards presented during the
Rachel K. King Wednesday Keynote Luncheon:
Chief Executive Officer
GlycoMimetics, Inc Governor of the Year Award
Biotech Humanitarian Award
10 B I O I N T E R N AT I ON A L CON V E N T I ON • June 27–30, 2011, Monday–Thursday2011 Super Sessions
High-Level Takes on Hot Topics
SUPER SESSIONS C-level speakers from major companies will lead broad conversations on the state of
the global industry, emerging trends and recommended courses of action for biotech
companies. Register for Full or Convention Access to attend these exciting talks.
For all confirmed Super Session speakers Tuesday, June 28 Wednesday, June 29
visit convention.bio.org/schedule. 3:45 pm – 5:15 pm 2:00 pm – 3:30 pm
Sponsored by: Eli Lilly and Company Sponsored by: Campbell Alliance
Tuesday, June 28
10:00 am – 11:30 am It Takes a Village—the Campbell Alliance 2011
Sponsored by: Ernst & Young Biotechnology Innovation Dealmakers’ Intentions
Ernst & Young’s 25th Annual Ecosystem The relationship between the biotechnology
and pharmaceutical industries has never been
Biotechnology Industry Report Innovation is the hallmark of biotechnology.
more apparent: partnering equals survival.
This Super Session will explore how key
Ernst & Young will present highlights from its 25th components of the biotech enterprise contribute The competition for unlicensed assets is
annual industry report. The session will discuss to the development of therapies that advance intense, and top dealmakers will shape the
implications for biotech companies as they face public health. Specifically, this session will future of the industry.
a more uncertain future in the current business detail the roles of government research labs, Building on a successful Super Session
climate. What new approaches do companies need universities and large and small biotechnology presented in 2010, Campbell Alliance and
for today’s economic realities? How are firms firms in the continuum from basic research to BIO will share new findings from two unique
partnering creatively in a capital-constrained, FDA-approved products and, meters of deal-making: the Campbell Alliance
risk-averse, high-scrutiny environment? How ultimately, to the patient. Dealmakers’ Intentions Survey and the BIO
will they need to engage regulators and payors to
Speaker One-on-One Partnering Forecast. New
meet their changing needs? What skill sets and
John Lechleiter, PhD analysis in 2011 will include year-over-
capabilities will these approaches require?
Chairman, year trends and the first assessment of the
As always, Ernst & Young will also summarize President & Chief Executive Officer predictive value of these instruments.
the sector’s performance using key metrics Eli Lilly and Company
John Lechleiter, PhD This session will then explore what assets are
— financial performance, financing, deals and
in demand among pharmaceutical companies
pipeline productivity. These issues will be further
Wednesday, June 29 and how emerging biotech companies
explored with a panel of industry leaders.
10:00 am – 11:30 am can best position themselves to
Speakers land the next blockbuster deal.
Sponsored by: Merck
Glen Giovannetti
Speaker
Partner and
Global Biotechnology Leader
Emerging Markets: The Future Ben Bonifant
Ernst & Young LLP of Growth for Biologics? Senior Vice President,
Gautam Jaggi Emerging markets are considered a source Practice Area Leader
Senior Manager and Editor, Campbell Alliance
of growth, but many represent barriers for Ben Bonifant
Beyond Borders and Progressions
Ernst & Young LLP Glen Giovannetti the life sciences industry, too. While biologics
are posing new issues for regulators and
policymakers worldwide, emerging markets Wednesday, June 29
Tuesday, June 28 are changing assumptions about regulatory 3:45 pm – 5:15 pm
2:00 pm – 3:30 pm
Sponsored by: Burrill & Company
expectations, intellectual property rights and Worldview 2011:
market access. At the same time, companies
Scientific American’s Regional
Burrill State-of-the-Industry Report recognize that emerging markets are more
than just new customers—they present new Bio-Innovation Scorecard
Biotech 2011—Life Sciences: Looking Back to
See Ahead. Burrill’s 25th anniversary annual opportunities to improve productivity and Worldview 2011 will feature the third annual
report highlights key global developments in advance innovations. In this session, leading Scientific American’s Regional Bio-Innovation
2010, including healthcare reform, comparative business executives and senior government Scorecard, a review of individual country
effectiveness, the specter of biogenerics and officials will discuss how emerging markets programs and policies aimed at growing local
genetic patents under threat that could retard are shaping businesses and what innovative biotechnology sectors. Fareed
biotech innovation. Mr. Burrill will lead us in a look impact they will have on the future Zakaria will moderate a panel discussing this
back over the past 25 years of critical events that of biotech. year’s report, which will focus on BRIC (Brazil,
have shaped the industry into the global enterprise Speaker Russia, India and China) country efforts
it is today. Finally, he will discuss how companies Richard T. Clark to build local biotechnology hubs.
can remain competitive in a tougher financial Chairman Speaker
Merck Richard T. Clark
climate with rapidly evolving Fareed Zakaria
technology, globalization and CNN host, Editor-at-Large of
TIME Magazine, Washington Post
new emerging markets. columnist, former Editor,
Speaker Newsweek International
G. Steven Burrill Fareed Zakaria
Chief Executive Officer
Burrill & Company
G. Steven Burrill
Super Sessions are open exclusively to Full or Convention Access registrants.
For more information and to register, visit convention.bio.org + 1.202.962.6655 11BIO Program
Leading Companies, Compelling Conversations: The BIO Program
The BIO Program delivers a full slate of 125+ inspiring sessions presented by some of
the brightest names in biotech and related fields. Super Sessions give you C-level, mile-
high perspectives on trends that are shaping the industry. Breakout Sessions address the
pressing topics that affect your day-to-day operations. In combination, the BIO Program
provides the well-rounded knowledge base you need to advance your business objectives.
16 Tracks Address Your Biggest Business Challenges
More than 125 thought-provoking sessions along 16 relevant tracks covering
the latest in business development, research, best practices and more.
Tracks include: • Finance
• Achieving Regulatory Control and • Food and Agriculture
Compliance • Global Innovations and Markets
• Biofuels and Biobased Chemicals • Health Policy and Reimbursement
• Biomarkers • Innovations in Vaccines
• Biosecurity • International Case Studies
• Biotech Patenting and Tech Transfer • Manufacturing of Biologics and Drugs View Special
• Business Development • NEW! Late Breaking Pull-Out Section
• Diagnostics and Personalized Medicine (Sessions to be announced soon at
• Drug Discovery and Development convention.bio.org/schedule.)
Join the Conversation and Start Planning Now
Add sessions to your event plan to make
See expert
the most of your time. Keep your handy
speakers from
schedule on your mobile device.
a myriad of
companies —
new speakers are
confirmed daily.
With our enhanced personal planning
tool, myBIO, you can browse sessions
by keyword, track and see the speakers
and personalities behind them. Create
a plan with sessions to attend and
exhibitors to meet, then—
• Export your plan to iCal or Outlook.
• Access your plan via your smart phone.
Visit convention.bio.org/myBIO.
Spark conversation with speakers and fellow
attendees by posting questions on the session profile.
12 B I O I N T E R N AT I ON A L CON V E N T I ON • June 27–30, 2011, Monday–ThursdayBreakout Sessions
Program Co-Chairs Message from the Program Co-Chairs
We’ve designed the 2011 Breakout Sessions with you in mind. Detailed on the following
pages, this lineup represents the most compelling of more than 900 session proposals,
which were carefully vetted by BIO and expert committees. All sessions offer insights
from top thought leaders, about your top concerns. They are meant to help you—
• Start and maintain successful development programs.
• Improve your day-to-day operations to keep your ventures moving.
• Develop successful partnerships and regulatory initiatives.
Mark Mlynarczyk John Carrol • Fast track towards your long- and short-term goals.
Director of Policy Editor, FierceBiotech
MedImmune We know you will take away a wealth of immediately-applicable information, and we
look forward to hearing your feedback. For full descriptions of each session, visit
convention.bio.org/schedule.
Look for these symbols next to Monday, June 27, 2011 2:00 pm – 3:30 pm
session descriptions. 2:00 pm – 3:15 pm 71 – How Will Congress Act on Upcoming
74 – Getting Approval for Drugs in an PDUFA Reauthorization
Advanced Sessions
Tailored for experienced biotechnology Ever-Increasing Risk-Averse World • Provide knowledge of the roles of Congress/
professionals, these session topics will • Give insight on the changing regulatory industry/patient groups with respect to PDUFA
spark in-depth strategic discussion. environment and critical success factors for negotiation.
new applications. • Identify priorities that may be raised in Congress
CLE Credit Sessions • Describe the challenges of a filing process from and potential impact on final PDUFA legislation.
Session organizers in the Achieving • Review where the Biotechnology Industry
Regulatory Approval and Compliance and the company’s and regulator’s point of view.
Biotech Patenting and Tech Transfer tracks • Learn how to get a cell therapy product Association is interacting with FDA and Congress
have arranged for attendees to receive evaluated as a drug. and the key priorities for the organization.
Continuing Legal Education (CLE) credits. 3:45 pm – 5:00 pm
3:45 pm – 5:00 pm
Hot Topic Sessions 76 – Rare Disease Drug Development 77 – Talking About Your Product in the
These sessions will cover the most current Goes Mainstream: What are the Regulatory New Age: Social Media and the Internet
issues facing the biotech industry. Considerations? • Understand current regulatory standards and
• Highlight unique regulatory opportunities/ policies related to dissemination of information
challenges for rare disease drug development. outside of labeling.
Achieving Regulatory Approval and Compliance • Clarify similarities/differences between biotech
• Understand current venues for disseminating
product information on the Internet and through
Sponsored by: Eli Lilly and Company and Foley and pharma.
social media.
Hoag LLP • Offer conclusions on how regulatory • Understand potential liability, and identify
Presenting companies include: environment for rare diseases has changed or measures to avoid it.
needs to evolve.
Amgen
Baker & McKenzie
Biotechnology Industry Organization Tuesday, June 28, 2011 The right service providers can
Boehringer Ingelheim 8:30 am – 9:45 am keep your project on track while
Coalition for Healthcare Communication 70 – Optimizing the Review Process for you navigate the regulatory maze. Find them
EMD Serono, Inc. Medical Countermeasures Requiring Use of
FDA Center for Biologics Evaluation & Research the Animal Rule for Approval/Licensure in the Clinical Trials and Business Services
(CBER) • Explain FDA’s role in facilitating the
Zones of the BIO Exhibition.
Field Fisher Waterhouse LLP, London Office development and approval/licensure of MCMs.
FlandersBio
• Explain the complexities of applying the Animal
FoldRx (recently acquired by Pfizer)
Rule to the approval/licensure of MCMs.
Wednesday, June 29, 2011
Gordon & Rees LLP
10:00 am – 11:30 am
National Health Council • Explain the industry perspective with regard to
National Human Genome Research Institute developing MCMs. 202 – EMA/FDA Town Hall
Pfizer • Outline key FDA and EMA organizational and
PTC Therapeutics 10:00 am – 11:30 am policy initiatives.
Shire-Movetis 72 – Navigating the New Law on • Discuss FDA- EMA collaborations.
Taligen TherapeuticsTiGenix Licensing Biosimilars
• Stimulate interactive discussion with respect to
Venable LLP • Explain how the regulatory pathway operates the initiatives and issues presented.
Wake Forest Institute for Regenerative Medicine and the legal issues in developing and
(WFIRM) marketing biologicals. 2:00 pm – 3:30 pm
• Review how scientific challenges affect 201 – FDA – TOWNHALL
Tweet about this track with regulators and the companies seeking approval • Outline key FDA organizational and policy initiatives.
for biosimilars. • Present FDA’s views on critical topics such as
hashtag #bio2011_policy FDAAA/PDUFA V, drug safety, transparency, and
• Discuss the EU experience with biosimilars
and what it may mean for companies seeking Critical Path regulatory science programs.
approval in the U.S. • Stimulate interactive discussion with respect to the
initiatives and issues presented.
For more information and to register, visit convention.bio.org + 1.202.962.6655 13BREAKOUT SESSIONS
Breakout Sessions
Thursday, June 30, 2011 Tuesday, June 28, 2011 • Detail research and breakthroughs in the
8:30 am – 9:45 am modification of plant biomass and sustainable
10:00 am – 11:30 am
production.
75 – Regulatory Issues for 205 – Better Living Through
Tissue Engineered Products Biology — Synthetic Biology for • Discuss routes to access the developments
Biofuel and Chemistry Production within the bionergy centers.
• Learn about current FDA approaches to the
regulation of tissue engineered products. • Outline synthetic biology-focused approaches
to chemical and biofuel production.
Thursday, June 30, 2011
• Understand good manufacturing practice 8:30 am – 9:45 am
concepts for manufacturing for tissue • Address the challenges to commercialization of
engineered products. synthetic biology-based technologies. 143 – White Biotechnology: From Laboratory
to Demonstration Scale
• Discuss additional hurdles on the way to • Engage in dialogue on the ethical and political
approval of tissue engineered products. challenges the industry faces. • Show the importance of networks between
industry and research institutes to facilitate
10:00 am – 11:30 am innovation.
Biofuels and Biobased Chemicals • Present two success stories of biobased
80 – Collocation Strategies for Cellulosic
Presenting companies include: Biofuel Production: Win-Win Scenarios products by innovative processes.
Through Plant Integration • Demonstrate high-throughput bioprocess
Arborgen
Bavarian Network White Biotechnology (BioM WB) • Describe how process modeling shows design as a way to sustainable new products.
Bioenergy Science Center attractive production cost scenarios for
Biotechnology Industry Organization collocated ethanol producers.
CA House of Representatives
Biomarkers
• Outline how combined processes allow for
California Green Energy Fund reduced carbon footprints relative to stand- Sponsored by: EMD Serono, Inc
Canale Communications alone processes.
Edenspace Presenting companies include:
• Discuss how capital costs are reduced for Agendia
Edenspace Systems Corporation collocated facilities, allowing for reduced risk to
Energy Biosciences Institute Biogen Idec
the investor. Boston Biotech Clinical Research LLC
Genomatica
JBEI 2:00 pm – 3:30 pm Cancer Research UK
Life Technologies 82 – Capitol Hill Trumps Wall Street? D Young & Co
Mascoma Corp. Finding the Harmony in Biorenewable Deloitte Consulting LLP
Metabolix R&D Eli Lilly and Company
Novozymes EMD Serono, Inc
• Outline the ways policymakers are creating Exiqon A/S
Oak Ridge National Laboratory
sustainable policy. Food and Drug Administration
Poet LLC
Sapphire Energy • Detail the requirements necessary to allow Foundation for the National Institutes of Health
Süd-Chemie AG capital markets to support R&D investment. GlaxoSmithKline
Synthetic Genomics • List the ways current biorenewables companies Johnson & Johnson
TU Munich have been successful financing without Marshall, Gerstein & Borun LLP
Wacker Chemie AG subsidies. Merck
Merz Pharmaceuticals
3:45 pm – 5:00 pm National Institute on Aging
Tweet about this track with 79 – Markets for Dual-Use Energy Crops National Institutes of Health
hashtag #bio2011_industl • Review the challenges of developing biomass Orasi Medical
feedstocks for biofuel/bioenergy. Prometheus
PROOF Centre of Excellence
• Introduce novel traits that can be engineered into RadMD LLC
COMMENTS FROM BIO crops to provide benefits for multiple markets. Shaare Zedek Medical Center
• Describe the improved economics for biofuel/ U.S. Food and Drug Administration
Brent Erickson bioenergy crops that have alternative markets. University of California, San Francisco
Executive Vice President, Industrial
and Environmental Section, BIO Wednesday, June 29, 2011 Monday, June 27, 2011
8:30 am – 9:45 am 2:00 pm – 3:15 pm
241 – From Direct Solar to Drop-Ins: The Next 87 – Use of Imaging in Clinical Development:
“Industrial biotech has enabled a Wave in Biofuels Technologies Risk Management Strategies for Site and
revolution in advanced biofuels and now • Demonstrate the breadth and rapid pace of Independent Image Evaluations
this revolution is moving into renewable innovation in biofuels development. • Teach participants about the pros and cons of
chemical platforms as well. Now that • Demonstrate solutions to limitations of first site and central read of imaging data in trials.
oil is hovering near $100 a barrel generation biofuels. • Explain current regulatory environment about
these biotechnologies are increasingly • Demonstrate the need for continued public site and central reads.
important and are becoming significant policy support of advanced biofuels. • Describe how to implement risk management
drivers in innovation for the chemical strategies when using imaging in trials.
industry.” 10:00 am – 11:30 am
78 – Progress of Research in Bioenergy 3:45 pm – 5:00 pm
Centers: An Update on the Major DOE 89 – IP Issues Affecting Biomarker-Based
and Other Bioenergy Research Centers Diagnostics
• Describe key fundamental science in • Inform biomarker scientists, business and legal
production and conversion of biomass into pros on the state of IP law in the biomarker field.
ethanol and advanced biofuels.
• Provide lively discussion and debate and answer
audience questions.
Advanced Hot Topic CLE Credit • Provoke debate and discussion on policy and
Session Session Session increase awareness of importance of IP to the field.
14 B I O I N T E R N AT I ON A L CON V E N T I ON • June 27–30, 2011, Monday–ThursdayTuesday, June 28, 2011 10:00 am – 11:30 am • Examine efforts to assess the threats facing
84 – The Role of Imaging Biomarkers in Early different regions.
8:30 am – 9:45 am
Clinical Phase CNS Drug Development • Describe approaches to the standardization
90 – Rediscovering the Promise of
Biomarkers • Give comprehensive landscape of CNS imaging of regulations, improving coordination of
biomarkers used in early-phase clinical CNS transportation, dispensing, and delivery across
• Learn about new models for international PPPs borders.
drug development.
to reduce risk and cost for biomarker research.
• State suitability of CNS imaging biomarkers to 3:45 pm – 5:15 pm
• Understand the regulatory challenges facing
measure drug penetration, pharmacodynamics 347 – Successes and Challenges in Public-
the biomarkers qualification and validation.
and dose response. Private Partnerships
• Explore how to work internationally to leverage
• Detail how effective CNS imaging biomarkers • Review successful public-private partnerships’
resources for biomarker reseach.
will accelerate CNS drug development: case management of complex arrangements or issues
10:00 am – 11:30 am studies. such as IP, legal issues and manufacturing
83 – The Biomarkers Consortium: Facilitating 2:00 pm – 3:30 pm responsibilities.
the Development and Qualification of 257 – Stratified Medicine – Hype or Hope • Highlight experiences implementing a complex,
Biological Markers multi-site, multi-product research and
• Learn about the emerging field of stratified
• Describe lessons learned from completed/ manufacturing enterprise.
medicine and its challenges and opportunities.
launched Biomarkers Consortium projects. • Discuss potential solutions that will help lead to
• Explore the future field dynamic and trends to
• Describe the challenges of biomarker success.
prepare for, looking at the different aspects of
qualification and the Biomarkers Consortium
biomarker development.
approach. Thursday, June 30, 2011
• Understand scenarios to consider at different
• Explain why a diverse mix of organizations and 8:15 am – 9:45 am
stages of development for an informed
sectors are involved in this effort. 348 – Financing Biodefense as a National
decision on biomarker development and
2:00 pm – 3:30 pm commercialization. Security Priority
86 – Rare Diseases Experience as a • Review existing methods for funding the
Model to Critically Affect Innovation in countermeasures enterprise, including new
Biomarker Strategy and Precision Biosecurity initiatives to stimulate increased private sector
Medicine involvement.
Presenting companies include:
• Explain rare diseases, orphan drug model: • Evaluate the criteria used by private capital
American Association for the Advancement of firms to assess new technologies and products.
challenges and payoff. Science (AAAS)
• Review examples of clinical biomarkers use in Biological Weapons Convention Implementation • Discuss ways that industry, government
patient stratification for efficacy and safety. Support Unit and equity firms can work together and
Biotechnology Industry Organization what milestones would be appropriate in the
• Discuss “Integrity” database to accelerate
Department of Homeland Security countermeasures arena.
biomarker identification.
The Henry L. Stimson Center 9:45 am – 11:15 am
3:45 pm – 5:00 pm Institute for Strategic Threat Analysis and
349 – Protecting the Unprotected:
85 – The Evolving Business Model for Response, University of Pennsylvania
Countermeasures for At-Risk and Vulnerable
Biomarkers: Status and Future Perspectives J. Craig Ventner Institute
Populations
• Highlight newest developments in the area National Security Council
Partnership for Global Security • Detail the unmet need for medical
of biomarkers and personalized/stratified
Woodrow Wilson International Center for Scholars countermeasures to protect all individuals.
medicine.
• Evaluate past efforts to protect at-risk and
• Outline impact on business models and
Wednesday June 29, 2011 vulnerable populations.
economics of therapy in the future of
personalized/stratified medicine. 8:15 am – 9:45 am • Discuss approaches to integrating vulnerable
populations into medical countermeasures
• Describe new working relationships between 343 – A View from the Hill planning, development, and dispensing.
biotech/pharma/diagnostic companies and the • Discuss Congressional views on domestic
evolving business models. biodefense and international biosecurity 11:30 am – 1:00 pm
initiatives. 475 – Managing Technological Innovation in the
• Review policy approaches to funding, New Era
Companies in the implementing, and evaluating key biodefense • Discuss the latest technologies, such as
Clinical Trials Zone of and biosecurity programs. synthetic biology and nanotechnology, and their
the BIO Exhibition can help get your • Evaluate needed policy initiatives to promote importance for facing new natural and man-
biomarker project on the fast track. and prioritize global biosecurity. made threats.
• Describe how technological innovation can
9:45 am – 11:15 am be used help prevent, identify or respond to
Wednesday, June 29, 2011 474 – Improving Global Bio-surveillance emerging diseases.
8:30 am – 9:45 am • Examine efforts to improve bio-surveillance • Evaluate how technological innovation may be
efforts around the world. used by rogue nations or select groups.
88 – Lessons From a Mature Public-
Private Partnership: The Alzheimer’s • Discuss roles in implementing bio-surveillance 1:30 pm – 2:00 pm
Disease Neuroimaging Initiative programs and integrating them with established
global surveillance networks. 351 – Closing Keynote Address: “The Role of
• Outline lessons learned from ADNI. the BWC in a Biotech-Driven World”
• Review bio-surveillance activities in the
• Provide information about the challenges/ • Explain the relevance of the 2011 BWC Review
zoonotic, food, and agricultural sectors.
advantages of biomarker qualification through Conference to multiple constituencies.
partnership. 2:00 pm – 3:30 pm • Discuss ways the BWC annual meeting process
• Explain why a diverse mix of organizations and 345 – Managing Global Challenges in an can enhance global biosecurity.
sectors are involved in this effort. Evolving Threat Environment • Evaluate the Review Conference’s response to
• Review the multiple challenges facing the new and emerging technological threats.
implementation of global biosecurity practices.
For more information and to register, visit convention.bio.org + 1.202.962.6655 15BREAKOUT SESSIONS
Breakout Sessions
3:45 pm – 5:00 pm 10:00 am – 11:30 am
Biotech Patenting and Tech Transfer**
93 – A Brave New World: Patent 96 – Lessons From In-Licensing Partnership:
Sponsored by: WilmerHale Litigation Tactics and Strategies Biotech Company Partners With Global Pharma
for Biosimilars to Deliver Cutting-Edge Biosimilars
**CLE Credits are offered by the organizing
companies of the following sessions. • Educate companies about the requirements of • Describe building strong alliances to advance the
the new biosimilar patent litigation pathway. development of novel therapies.
Presenting companies include:
• Explore strategic and tactical choices companies • Convey key learnings, challenges and opportunities
20/20 Gene Systems face along the new patent litigation timeline. of a global partnership in orphan drugs.
Agricultural Research Service, USDA
ANAND AND ANAND • Consider questions and concerns companies • Celebrate the differences: strategically leveraging
Bayer HealthCare Pharmaceuticals face in planning to navigate the new pathway. big pharma and biotech in a partnership.
Biogen Idec 2:00 pm – 3:30 pm
Choate Hall & Stewart LLP Tuesday, June 28, 2011
91 – Collaborative R&D From the
DCGI (Retired) European Patent Office 8:30 am – 9:45 am Perspective of Large Multinationals,
Marshall, Gerstein & Borun LLP 218 – The Myriad Case and the Universities and Start-ups
Mayo Clinic Patentability of Isolated DNA Molecules
Merck • Teach participants how to approach technology
• Enable a spirited discussion of this and other owners and what their needs are.
Monsanto Company
high-profile patent cases affecting BIO’s
Novartis Institutes for Biomedical Research • Describe how to attract sponsors for research
members, including the Supreme Court’s 2010-
Novita Therapeutics and licensing revenues to your university.
2011 patent docket.
Novozymes • Discuss key aspects of collaboration and
NUtech Ventures • Educate the audience about recent
licensing agreements.
Office of Technology Transfer, NIH developments in the Myriad case and BIO’s
Pfizer leadership role as an amicus.
Thursday, June 30, 2011
Protalix Biotherapeutics • Inform BIO’s membership of the importance of
The Frankel Group continued involvement with the issues raised, 8:30 am – 9:45 am
The Procter & Gamble Corporation whether at the Supreme Court stage or in an 95 – Innovative Collaborations: Deal
Thompson Coburn LLP effort to obtain legislative remedies. Structures for Nonprofit/For-Profit
WilmerHale Collaborations
10:00 am – 11:30 am
• Describe successful industry collaborations with
COMMENTS FROM BIO 259 – Patents in the nonprofits and drafting those clauses in your
Supreme Court agreement.
Tom Dilenge • Learn about the multiple currently-pending • Explain how collaboration terms vary when one
General Counsel and Senior patent cases in the U.S. Supreme Court and their or both of the parties is a non-U.S. entity.
Vice President, Legal & profound implications for the biotech industry.
Intellectual Property, BIO • List structures and terms to avoid in the interest
• Learn why the Supreme Court is reviewing high- of a successful collaboration.
profile patent cases at an unusually high rate.
• Explore the direction in which the Supreme 10:00 am – 11:30 am
“The lifeblood of biotechnology 306 – Protecting your Biotech IP in Europe —
Court is developing patent law, and prepare for
innovation is strong patent protection future big patent law issues in the Supreme One of the Largest Markets in the World.
and commercially-attractive licensing Court. • Define the expected changes in patent (case)
practices. Our track will focus on law, at European and national levels.
2:00 pm – 3:30 pm
what biotech executives, investors, IP • Analyze the consequence of these changes on
473 – Counterfeiting — How Corporations and
attorneys and others in the industry the Government Can Work Together global patenting and licensing strategies.
need to know about the latest key trends • Anticipate new IP trends and translate them in
• Knowledge of roles industry/law enforcement/
and best practices in this critical area.” judiciary; fight importation of counterfeit terms of business development.
products.
• To clearly identify specific steps industry can Business Development
Monday, June 27, 2011 take in working with law enforcement agencies.
Sponsored by: Pfizer and Pillsbury Winthrop Shaw
2:00 pm – 3:15 pm Pittman LLP
92 – Drug Patent Linkage and Compulsory Visit the Business Services Presenting companies include:
Licensing — Challenges of Working Patented Zone of the BIO Exhibition
Inventions in India for Pharma Sector 5AM Ventures
to meet law firms specializing in Aegerion Pharmaceuticals, Inc.
• Pharma patent enforcement scene in India in Amgen
view of linkage and CL provisions and recent intellectual property.
Anchor Therapeutics
Court orders. AstraZeneca
• Knowing recent circular on patent working Avila Therapeutics, Inc.
information and patent CL discussion paper
Wednesday, June 29, 2011 Biotie Therapies
and decisions. 8:30 am – 9:45 am Bristol-Myers Squibb Company
• Effect of CL discussion paper on Public- 94 – Innovative Marketing and Technology Celgene Corporation
private deals in view of the Indian version of Transfer — Federal Agencies Have Joined the Eisai
Bayh-Dole Act. Game EnVivo Pharmaceuticals, Inc
• Teach about the new tools for business EURORDIS
development and technology transfer. Foley Hoag LLP
Fulcrum Pharmaceuticals, Inc
• Clarify the importance of streamlining internal Genentech
processes for business development. GlaxoSmithKline
• Describe how to create a better user Hyperion Therapeutics
Advanced Hot Topic CLE Credit experience for website visitors using Web 2.0 Johnson & Johnson
Session Session Session tools. Macdougall Biomedical Communications
16 B I O I N T E R N AT I ON A L CON V E N T I ON • June 27–30, 2011, Monday–ThursdayMarina Biotech, Inc. 2:00 pm – 3:30 pm 10:00 am – 11:30 am
Merck 188 – The Changing BD Environment: 187 – Relationship Management: An Essential
Micromet Overcoming Our Past to Succeed in the Future Key Enabler for Alliance Success
New Enterprise Associates
• Explain the dynamics (type, economics, timing, • Give practical implementable lessons about
Novartis Pharma
roles) driving biotech/pharma collaborations. building AM capability in organizations.
OncoMed Pharmaceuticals
Orexigen Therapeutics, Inc. • Conceptualize novel approaches to biotech and • Describe establishing metrics to support the
Pfizer pharma collaborations. value proposition provided by AM best practice.
Pillsbury • Identify key deal showstoppers from either a • Describe Alliance Portfolio Management
Plexxikon historical or novel transaction approach. through AM best practice.
Roche
Roche Pharma Partnering 3:45 pm – 5:00 pm
sanofi pasteur 185 – Is Something Wrong With Our Alliance?: Meet service providers with
Skyline Ventures How to Find Out Quickly business development
Sutro Biopharma • Identify problems early-on using health-check experience in the Business Services Zone
Tolerx, Inc methods appropriate for different alliances.
Vertex Pharmaceuticals Incorporated of the BIO Exhibition.
• Describe different methods, their requirements,
Xconomy
advantages and drawbacks, and when to
employ them.
Tweet about this track with • Convey through in-depth biopharma-specific
myBIO keyword search: Business Services
hashtag #bio2011_bd examples how to maintain successful alliances.
Wednesday, June 29, 2011
Monday, June 27, 2011 Diagnostics and Personalized Medicine
8:30 am – 9:45 am
2:00 pm – 3:15 pm 184 – Secrets of the Big Pharma Dealmakers Sponsored by: Abbott and Enterprise Florida
174 – The Effect of a More Risk Averse
• Identify approaches for identifying good Presenting companies include:
Environment on Licensing Deals
partners and how to get noticed by big pharma. Abbott
• Describe the current environment within Accentia Biopharmaceuticals
• Spotlight latest trends in deal structures and
licensing biopharma companies with regard to Agenzia Italiana del Farmaco – AIFA
key contract terms now being negotiated.
risk for in-licensed programs. AltheaDx, Inc.
• Explain the “do’s” and “don’ts” of managing
• Indicate specific risk management strategies AstraZeneca
partnerships.
and their implications. Baker Botts LLP
• Give advice from licensees on how best to 10:00 am – 11:30 am Banyan Biomarkers
strategize with a licensing partner. 186 – Premature or Prescient? When Big BioMarker Strategies, LLC
Pharma Is Doing Preclinical Deals With BioVest International
3:45 pm – 5:00 pm Seemingly Clinical-Stage Valuations Boston Healthcare
190 – Disco Inferno — Pharma Feels the Heat Cardio Dx
• Provide alternative approaches to gaining
With Discovery Deals Clovis Oncology
access to important resources that will support
• Present the current ‘state of the state’ on Compendia Bioscience
drug discovery.
pharma pipelines and appetite for discovery Eli Lilly and Company
• Provide emerging companies with ideas about European Commission DG Enterprise and Industry
stage deals.
collaborating with pharma. Genomic Health, Inc
• Discuss challenges for biotech companies to Health Advances
• Showcase successful collaborations that
preserve autonomy and IP when partnering. Ipsen Innovation, Ipsen Group
provide pharma access to promising early-
• Query representatives on both sides of the fence stage assets. Medco Health Solutions, Inc.
as to how to get successful deals accomplished. Medco Research Institute
2:00 pm – 3:30 pm Novartis Molecular Diagnostics
Tuesday, June 28, 2011 260 – Moving to the Next Level: Accessing On-Q-ity
8:30 am – 9:45 am Capital Internationally Personalized Medicine Coalition
• Learn how to position your company to access Pure Communications Inc.
176 – The Partnering Conundrum: To Partner
capital from these types of investors. Research & Development, Inc
or Not to Partner, That Is the Question . . .
Sanford-Burnham Medical Research Institute
• Describe the benefits and drawbacks of • Discover how to keep a deal alive.
School of Medicine, The University of Manchester
partnerships from various perspectives. • Find out what types of deals and companies Scientia Advisors
• Describe key value driving/preserving terms to investors at this level look for. XDx, Inc
keep in mind while negotiating a partnership.
• Discuss how to achieve a successful exit after
Thursday, June 30, 2011 COMMENTS FROM BIO
a company has partnered a key asset. 8:30 am – 9:45 am
Daryl Pritchard, PhD
189 – Accelerating Product Development With Director, Research Programs
10:00 am – 11:30 am Nondilutive Funding for Private Biotechs Advocacy, BIO
191 – Navigating New Trends in the Industry:
• Outline types of funding sources available for
How Pharma and Biotech Collaborations Are
early-stage biotech companies.
Shaping the Future of Drug Development
• Discover how pharma and biotech partnerships
• Review the pros and cons of applying for public “Personalized Medicine and the
and/or private sources of nondilutive funding. integration of advanced diagnostics into
can increase drug development diversification.
• Offer insights from industry experts on
• Detail the process for applying for and wellness and health condition decision
successfully receiving funding. making IS the future of healthcare. This
the strategic value of pharma and biotech
collaborations. evolution of the healthcare system
• Discover how to meet patients’ needs through will happen through advances in
advancements in novel therapies and industry Biotechnology.”
partnerships.
For more information and to register, visit convention.bio.org + 1.202.962.6655 17You can also read
